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Background-—In heart failure (HF), weight loss (WL) has been associated with an adverse prognosis whereas obesity has been
linked to lower mortality (the obesity paradox). The impact of WL in obese patients with HF is incompletely understood. Our
objective was to explore the prevalence of WL and its impact on long-term mortality, with an emphasis on obese patients, in a
cohort of patients with chronic HF.
Methods and Results-—Weight at ﬁrst visit and the 1-year follow-up and vital status after 3 years were assessed in 1000
consecutive ambulatory, chronic HF patients (72.7% men; mean age 65.812.1 years). Signiﬁcant WL was deﬁned as a loss of ≥5%
weight between baseline and 1 year. Obesity was deﬁned as body mass index ≥30 kg/m2 (N=272). Of the 1000 patients included,
170 experienced signiﬁcant WL during the ﬁrst year of follow-up. Mortality was signiﬁcantly higher in patients with signiﬁcant WL
(27.6% versus 15.3%, P<0.001). In univariable Cox regression analysis, patients with signiﬁcant WL had 2-fold higher mortality
(hazard ratio 1.95 [95% CI 1.39–2.72], P<0.001). In multivariable analysis, adjusting for age, sex, body mass index, New York Heart
Association functional class, left ventricular ejection fraction, HF duration, ischemic etiology, diabetes, and treatment, signiﬁcant
WL remained independently associated with higher mortality (hazard ratio 1.89 [95% CI 1.32–2.68], P<0.001). Among obese
patients with HF, signiﬁcant WL was associated with an even more ominous prognosis (adjusted hazard ratio for death of 2.38 [95%
CI 1.31–4.32], P=0.004) than that observed in nonobese patients (adjusted hazard ratio 1.83 [95% CI 1.16–2.89], P=0.01).
Conclusions-—Weight loss ≥5% in patients with chronic HF was associated with high long-term mortality, particularly among obese
patients with HF. ( J Am Heart Assoc. 2016;5:e002468 doi: 10.1161/JAHA.115.002468)
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O besity increases the risk of heart failure (HF)
1 and
cardiovascular death in the general population.2 How-
ever, a signiﬁcant survival beneﬁt of obesity in patients with
established HF has been extensively described in different
settings: short- and long-term follow-up, acute and chronic HF,
and in reduced and preserved ejection fraction.3–7 The preva-
lence of overweight or obesity in patients with HF can reach
about 35% to 45%8,9 when deﬁned using bodymass index (BMI).
Among weight indices, BMI has been shown to properly
correlate with the thickness of the subcutaneous fat layer10
and has been rapidly adopted as the primary obesity index in
HF. Other parameters used for measuring body composition
(waist circumference, skinfold estimates of percentage of
body fat, DEXA, and bioelectrical impedance analysis) have
also demonstrated an independent relationship with mortality
in HF patients,11–13 although none has proved to be clearly
superior to BMI; thus, the use of BMI in HF remains routine
clinical practice.
Despite the potential beneﬁts of weight loss (WL) in obese
and overweight patients, this recommendation may not apply
to patients with HF. Indeed, both the American College of
Cardiology/American Heart Association and the European
Society of Cardiology guidelines in HF do not provide
conclusive recommendations about WL.14,15 Moreover, the
prognostic impact of WL in obese patients with HF is not
completely known, despite possible beneﬁcial effects of WL
on hemodynamics, cardiac structure, diastolic function, and
even systolic function.16 Robust evidence regarding the
relation of WL and long-term prognosis in patients with
chronic HF is missing.17–19 Accordingly, our aim was to
analyze the prevalence of WL over a 1-year follow-up period
and its impact on mortality in a large, real-life, outpatient
population with HF, with special attention to obese patients.
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Subjects and Methods
Design and Study Population
All consecutive, ambulatory patients referred between August
1, 2001 and September 30, 2011 to a structured HF clinic at
a university hospital, irrespective of etiology, with available
weight data at the ﬁrst visit and at a 1-year follow-up visit
were included in an outpatient setting. The criteria for clinical
practice referral to the HF clinic have been reported
elsewhere.20,21 Brieﬂy, the criteria were HF with at least
one hospitalization and/or reduced left ventricular ejection
fraction (LVEF) of <40%. Most patients were referred from
cardiology and internal medicine departments, and fewer
were from the emergency room/short-stay unit or other
hospital departments. Less than 10% of patients were
admitted to the HF unit due to asymptomatic, reduced LVEF
after acute myocardial infarction.
BMI was analyzed according to weight and height using the
formula weight (kg)/(height [m])2. We then evaluated the
relationship between BMI and survival throughout follow-up.
Patients were classiﬁed according to BMI into 4 strata
following the criteria deﬁned by the World Health Organization
(WHO Technical Report Series, no 854, Geneva, 1999) as
follows: low weight (BMI <20.5 kg/m2), normal weight (BMI
20.5 to <25.5 kg/m2), overweight (BMI 25.5 to <30 kg/m2),
and obese (BMI ≥30 kg/m2). Signiﬁcant WL was deﬁned as a
loss of ≥5% from the initial weight (ie, baseline) to end of ﬁrst
year of follow-up.
All patients were seen regularly during follow-up visits at the
HF clinic according to their clinical needs. The follow-up visit
schedule (nurses and physicians) has been reported else-
where.21,22 Losing weight with dietary restrictions was not
routinely advised for overweight, nor for the majority of obese
patients, although a healthy diet and physical exercise is always
recommended. Only some morbid obese patients were man-
aged by the Endocrinology and Nutrition Service. The nutrition-
ist at the HF Unit was primarily involved in undernourished
patients with lack of appetite. Patients in NYHA class II to IV
were evaluated by a rehabilitation physician and an exercise
program was offered. Nevertheless, less than one third of the
patients in the present study actually participated in such an
established program. All patients provided written consent for
analytical samples and the use of their clinical data for research
purposes. The study was performed in compliance with laws
protecting personal data in accordance with the international
guidelines on clinical investigation of the World Medical
Association’s Declaration of Helsinki, it was approved by the
local ethics committee, and all patients signed informed
consent. At the ﬁrst visit, we recorded the patient’s demo-
graphic characteristics, baseline clinical status, physical exam-
ination data, and treatment following a standardized protocol.
Mortality Assessment
Death from all causes was the main outcome. The number
and causes of death during follow-up were obtained from
clinical records at the HF clinic, other hospital departments,
other hospital records, or by contacting the patient’s relatives.
Data were veriﬁed using the databases of the Catalan and
Spanish Health System. One patient was lost during follow-up
and was adequately censored in the survival analysis. Follow-
up was closed September 30, 2014.
Statistical Analysis
Categorical variables were described by frequencies and
percentages. Continuous variables were described by the
meanSD, or median and 25th to 75th percentiles (Q1–Q3)
for cases with skewed distribution. Normal distribution was
assessedwith normal Q-Q plots. Statistical differences between
groupswere assessed using thev2 test for categorical variables,
Student t test for continuous variables with normal distribution,
or the Mann–Whitney U test for non-normal distributions. Cox
proportional hazards regression analyses were performed using
all-cause mortality and also cardiovascular mortality as the
dependent variable and signiﬁcant WL, as deﬁned, as the
independent variable. Afterwards, multivariable analyses were
also performed, including as covariates age, sex, New York
Heart Association (NYHA) functional class, HF duration, LVEF,
etiology of HF, diabetes, baseline BMI, and treatment with b-
blockers, angiotensin-converting enzyme inhibitors–an-
giotensin II receptor blockers, and mineralocorticoid receptor
antagonists. These analyses were repeated after categorizing
BMI in 2 groups: obese or nonobese, which included under-
weight, normal weight, and overweight. Also, adjusted survival
curves for all-cause and cardiovascular death were plotted
according to the presence or absence of signiﬁcant WL for both
obese and nonobese patients. Finally, the Cox regression
multivariable analyses were repeated using standardized WL as
continuous variable (with 1 SD decrease). Statistical analyses
were performed using SPSS 15 (SPSS Inc, Chicago, IL). A 2-
sided P<0.05 was considered statistically signiﬁcant.
Results
Of 1322 patients admitted to the HF Unit, a total of 1000
patients (72.7% men; mean age 65.812.1 years) were
included in the study. Causes for noninclusion were as
follows: 139 patients died during the ﬁrst year of follow-up,
152 did not attend the 1-year visit, and 31 had no weight
available (wheelchair or impossibility to stand up). The
demographic and clinical characteristics of the patients are
summarized in Table 1. The patients were predominantly
DOI: 10.1161/JAHA.115.002468 Journal of the American Heart Association 2
Weight Loss, Heart Failure, and Obesity Zamora et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Table 1. Demographic and Clinical Characteristics
Total Cohort Signiﬁcant WL No Signiﬁcant WL
P ValueN=1000 N=170 N=830
Age*, y 65.812.1 67.311.0 65.512.3 0.08
Female sex 273 (27.3%) 61 (35.9%) 212 (25.5%) 0.006
Etiology 0.31
IHD 557 (57.5%) 82 (48.2%) 475 (57.2%)
DCM 111 (11.1%) 22 (12.9%) 89 (10.7%)
HYP 88 (8.8%) 21 (12.4%) 67 (8.1%)
Alcohol induced 59 (5.9%) 13 (7.6%) 46 (5.5%)
Toxic (MEDS) 19 (1.9%) 3 (1.8%) 16 (1.9%)
Valvular 86 (8.6%) 13 (7.6%) 73 (8.8%)
Other 80 (8.0%) 16 (9.4%) 64 (7.7%)
NHYA functional class <0.001
I 56 (5.6%) 6 (3.5%) 50 (6.0%)
II 649 (64.9%) 90 (52.9%) 559 (67.3%)
III 283 (28.3%) 70 (41.2%) 213 (25.7%)
IV 12 (1.2%) 4 (2.4%) 8 (1.0%)
HF duration, months† 10.5 (2–48) 14.5 (2–54) 10 (1–48) 0.16
LVEF*, % 32.412.6 33.914.2 32.212.3 0.10
BMI, kg/m2 27.65.1 29.34.9 27.25.0 <0.001
Diabetes 368 (36.8) 65 (38.2) 368 (36.8) 0.67
Smoking habit
Current 159 (15.9) 28 (16.5) 131 (15.8) 0.82
Past 418 (41.8) 70 (41.1) 348 (41.9) 0.86
NTproBNP, ng/L†‡ 1586 (576–3661) 1766 (694–4792) 1524 (554–3519) 0.35
ST2, ng/mL†‡ 39.7 (31.9–52.5) 42.6 (31.7–62.4) 39.2 (31.9–51.1) 0.29
Hs-CRP, mg/L†‡ 4.19 (1.69–9.91) 4.37 (1.84–8.03) 4.14 (1.62–10.46) 0.94
Hs-TnT, ng/L†‡ 26.5 (13.1–44.3) 32.6 (19.0–55.8) 26.2 (12.1–42.9) 0.05
STfR, mg/L†‡ 3.7 (2.9–4.9) 3.9 (3.1–4.8) 3.7 (2.9–4.9) 0.31
Treatments (follow-up)
ACEI or ARB 914 (91.4%) 153 (90.0%) 761 (91.7%) 0.48
b-Blockers 910 (91.0%) 148 (87.1%) 762 (91.8%) <0.05
MRA 585 (58.5%) 114 (67.1%) 471 (56.7%) 0.01
Loop diuretics 911 (91.1%) 163 (95.9%) 748 (90.1%) 0.02
Digoxin 397 (39.7%) 89 (52.4%) 308 (37.1%) <0.001
ICD 132 (13.2%) 22 (12.9%) 110 (13.3%) 0.91
CRT 81 (8.1%) 10 (5.9%) 71 (8.6%) 0.25
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; DCM, dilated cardiomyopathy;
HF, heart failure; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high sensitivity cardiac troponin T; HYP, hypertension; ICD, implantable cardiac deﬁbrillator; IHD, ischemic heart
disease; LVEF, left ventricular ejection fraction; MEDS, medications; MRA, mineralocorticoid receptor antagonist; NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York
Heart Association; ST2, high-sensitivity soluble ST2; STfR, soluble transferrin receptor; WL, weight loss.
*MeanSD.
†Median (Q1–Q3).
‡NTproBNP available in 422 patients; ST2 available in 340 patients; hs-CRP, hs-TnT, and STfR available in 332 patients.
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male, with a median duration of HF of 10.5 months (Q1–Q3
2–48 months), and a mean LVEF of 32.412.6%. One
hundred seventy patients (17%) experienced signiﬁcant WL
during the ﬁrst year of follow-up. Figure 1 illustrates the
percentage of patients with WL ≥5%, showing a signiﬁcantly
higher rate in overweight and obese patients.
Table 1 shows the clinical differences between patients
with and without signiﬁcant WL. In addition to sex, most were
related to HF severity and treatment. In a limited sample of
patients, we have data on biomarkers, without differences
between both groups; only high-sensitivity troponin T tended
to be higher in patients with signiﬁcant WL (P=0.05, Table 1).
After 3 years of follow-up from the ﬁrst visit (ie, 2 years
after the second weight assessment), 174 patients (17.4%)
died—121 from cardiovascular causes (54 worsening HF, 30
sudden death, 11 acute myocardial infarction, 5 stroke, and
21 other), 40 from noncardiovascular causes, and 13 from
unknown causes. Mortality in signiﬁcant WL patients was
signiﬁcantly higher than in patients without signiﬁcant WL
(27.6% versus 15.3%, P<0.001). This was basically due to
cardiovascular mortality (20.0% versus 10.9%, respectively,
P=0.01), whereas differences in noncardiovascular mortality
were nonsigniﬁcant (6.0% versus 3.7%, respectively, P=0.16).
Of note, death due to worsening HF was 11.2% and 4.2%,
respectively, P<0.001.
In univariable Cox regression analysis, patients with
signiﬁcant WL had 2-fold all-cause and cardiovascular higher
mortality (hazard ratio [HR] 1.95 [95% CI 1.39–2.72], P<0.001
and HR 2.06 [95% CI 1.39–3.06], P<0.001, respectively). In
the multivariable model adjusted by and age, sex, BMI, NYHA
functional class, LVEF, HF duration, ischemic etiology,
diabetes, and treatment with b-blockers, angiotensin-convert-
ing enzyme inhibitors–angiotensin II receptor blockers, and
mineralocorticoid receptor antagonists, signiﬁcant WL
remained highly and independently associated with higher
all-cause mortality (HR 1.89 [95% CI 1.32–2.68], P<0.001)
(Table 2). Among obese HF patients, signiﬁcant WL was
associated with an even higher risk of all-cause death
(adjusted HR 2.38 [95% CI 1.31–4.32], P=0.004) than that
observed in nonobese patients (adjusted HR 1.83 [95% CI
1.16–2.89], P=0.01) (Table 2). Figure 2 shows adjusted
survival curves for all-cause death relative to the presence
or absence of signiﬁcant WL for nonobese and obese patients.
Focus in cardiovascular death provided similar results:
Signiﬁcant WL remained highly and independently associated
with higher cardiovascular mortality (HR 1.89 [95% CI 1.29–
2.90], P=0.003) (Table 3), and again among obese HF
patients, signiﬁcant WL was associated with higher risk of
cardiovascular death (adjusted HR 2.51 [95% CI 1.23–5.14],
P=0.01) than that observed in nonobese patients (adjusted
HR 1.75 [95% CI 1.00–3.06], P<0.05) (Table 3). Figure 3
shows adjusted survival curves for cardiovascular death
relative to the presence or absence of signiﬁcant WL for
nonobese and obese patients. Tables 4 and 5 show Cox
regression multivariable analyses for all-cause and cardiovas-
cular death, respectively, using standardized WL as continu-
ous variable (with 1 SD decrease).
Discussion
The main conclusion of this study may seem perplexing, which
is that signiﬁcant WL might be not beneﬁcial even in obese
patients with HF. This ﬁnding may, in part, provide a rationale
for the obesity paradox in HF, which is extensively
described,3–7 not universally observed,22–26 and incompletely
understood. Obese patients with HF are thought to have
metabolic reserves to better tolerate the catabolic stress of
HF, thus explaining the better prognosis. However, the
occurrence of unintentional WL may be a surrogate for the
loss of metabolic reserves in obese patients and may be the
trigger for adverse clinical outcomes. On the other hand,
being obese while having HF seems incongruous with
undernourishment, which is associated with a very poor
prognosis in patients with chronic HF.27 Indeed, it is possible
that WL secondary to malnutrition might exacerbate under-
lying undernourishment. Purposeful WL is usually recom-
mended for patients with HF and morbid obesity. As
suggested by Lavie et al, this seems particularly sound for
those with a BMI ≥40 kg/m2 and reasonable for most HF
patients with BMI of ≥35 kg/m2.16
Figure 1. Prevalence of signiﬁcant WL according to body mass
index strata. Signiﬁcant WL was considered the loss of ≥5% of the
initial weight during the ﬁrst year of follow-up. WL indicates
weight loss.
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A few reports with small sample populations exist on the
effect of intentional weight reduction on quality of life and
cardiac function in patients with HF. Mariotti et al evaluated
the impact of a planned body weight reduction plan on
quality of life and cardiac function in 34 obese and
overweight chronic HF patients through a 6-month nutri-
tional and physical activity program. Those patients who
achieved a loss of at least 3 kg (about 3.2% of WL) showed
a signiﬁcant improvement in LVEF and mean NYHA
functional class and quality of life. The study did not
evaluate mortality.28 Another small randomized clinical trial
evaluated the beneﬁt of losing weight via a lipase inhibitor–
assisted diet in 21 severely obese patients. Signiﬁcant WL
(5% absolute reduction in body weight) and improvement in
the 6-minute walking test and functional class were
observed in the treated group at 12 weeks.29 Again, no
Table 2. Multivariable Cox Regression Analysis for All-Cause Death
Total Nonobese Obese
N=1000 N=725 N=275
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Weight loss ≥5% 1.88 (1.32–2.68) <0.001 1.83 (1.16–2.89) 0.01 2.38 (1.31–4.32) 0.004
Age 1.04 (1.02–1.05) <0.001 1.04 (1.02–1.06) <0.001 1.04 (1.01–1.08) 0.02
Female sex 0.70 (0.48–1.02) 0.06 0.70 (0.44–1.12) 0.14 0.45 (0.22–0.95) 0.04
Ischemic etiology 1.63 (1.16–2.30) 0.005 1.46 (0.96–2.23) 0.08 2.66 (1.37–5.17) 0.004
HF duration 1.00 (1.00–1.01) 0.001 1.00 (1.00–1.01) <0.001 1.00 (1.00–1.01) 0.66
LVEF 1.00 (0.98–1.01) 0.39 1.00 (0.98–1.01) 0.22 1.00 (0.98–1.03) 0.86
NYHA functional class 1.62 (1.24–2.12) <0.001 1.62 (1.82–2.47) <0.001 1.07 (0.59–1.95) 0.82
Diabetes 1.29 (0.95–1.76) 0.11 1.08 (0.73–1.58) 0.11 2.08 (1.16–3.73) 0.01
BMI 1.00 (0.97–1.03) 0.90 0.93 (0.97–1.03) 0.02 1.06 (0.97–1.15) 0.19
b-Blockers 0.43 (0.29–0.66) <0.001 0.49 (0.30–0.81) 0.006 0.36 (0.16–0.83) 0.02
ACEI or ARB 0.41 (0.28–0.61) <0.001 0.38 (0.24–0.60) <0.001 0.50 (0.21–1.21) 0.12
MRA 0.77 (0.56–1.05) 0.09 0.80 (0.56–1.16) 0.24 0.73 (0.40–1.33) 0.30
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; MRA,
mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
Figure 2. Adjusted survival curves for all-cause death according to the presence of
signiﬁcant weight loss. A, Nonobese patients. B, Obese patients. Survival curves plotted
from the multivariate analysis that included age, sex, New York Heart Association functional
class, left ventricular ejection fraction, etiology of heart failure, diabetes, and treatment with
b-blockers, angiotensin-converting enzyme inhibitors–angiotensin II receptor blockers, and
mineralocorticoid receptor antagonists as covariates.
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analysis of mortality could be performed due to the small
sample size and short follow-up.
Data on unintentional WL in obese patients are even
scarcer. In a post-hoc analysis of the SOLVD trial, Anker
et al30 were the ﬁrst to suggest that any WL independent of
the patients’ weight at baseline is related to poor survival,
although no speciﬁc comment on obese patients was
reported. More recently, Rossignol et al31 observed signiﬁ-
cant WL in 16.4% and 15.7% of patients from the GISSI-HF
and Val-HeFT studies, respectively, with results quite similar
Table 3. Multivariable Cox Regression Analysis for Cardiovascular Death
Total Nonobese Obese
N=987* N=716 N=271
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Weight loss ≥5% 1.89 (1.24–2.90) 0.003 1.75 (1.00–3.06) <0.05 2.51 (1.23–5.14) 0.01
Age 1.04 (1.02–1.06) <0.001 1.05 (1.02–1.07) <0.001 1.05 (1.01–1.09) 0.01
Female sex 0.58 (0.36–0.92) 0.02 0.59 (0.33–1.06) 0.08 0.36 (0.14–0.92) 0.03
Ischemic etiology 2.10 (1.37–3.23) 0.001 1.84 (1.08–3.15) 0.03 3.58 (1.59–8.08) 0.002
HF duration 1.00 (1.00–1.01) <0.001 1.00 (1.00–1.01) <0.001 1.00 (1.00–1.01) 0.55
LVEF 1.00 (0.98–1.01) 0.53 1.00 (0.98–1.01) 0.64 0.99 (0.96–1.02) 0.63
NYHA functional class 1.62 (1.17–2.25) 0.004 1.84 (1.26–2.68) <0.001 1.00 (0.50–2.02) 0.99
Diabetes 1.59 (1.10–2.31) 0.01 1.41 (0.90–2.23) 0.14 2.37 (1.19–4.71) 0.01
BMI 1.02 (0.99–1.07) 0.23 0.97 (0.97–1.05) 0.47 1.10 (0.99–1.07) 0.04
b-Blockers 0.37 (0.23–0.60) <0.001 0.40 (0.22–0.73) 0.003 0.34 (0.13–0.91) 0.03
ACEI or ARB 0.41 (0.26–0.66) <0.001 0.36 (0.21–0.62) <0.001 0.79 (0.23–2.65) 0.79
MRA 0.90 (0.62–1.31) 0.57 0.96 (0.61–1.49) 0.84 0.84 (0.41–1.73) 0.64
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection
fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
*Thirteen patients excluded because of unknown cause of death.
Figure 3. Adjusted survival curves for cardiovascular death according to the presence of
signiﬁcant weight loss. A, Nonobese patients. B, Obese patients. Survival curves plotted
from the multivariate analysis that included age, sex, New York Heart Association functional
class, left ventricular ejection fraction, etiology of heart failure, diabetes, and treatment with
b-blockers, angiotensin-converting enzyme inhibitors-angiotensin II receptor blockers, and
mineralocorticoid receptor antagonists as covariates. Thirteen patients were excluded from
the analysis because of unknown cause of death.
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to ours. As in Val-Heft, we found that signiﬁcant WL (using
similar criteria) was associated with female sex, worse NYHA
functional class, higher BMI, and less use of b-blockers. It has
been suggested that b-blockers may exert anticachexic
effects by inhibiting catecholamine-induced lipolysis.32 We
also found an association between signiﬁcant WL and
treatment with mineralocorticoid receptor antagonists and
loop diuretics—the latter of which was also observed in
Table 4. Multivariable Cox Regression Analysis for All-Cause Death, Using Weight Loss as Continuous Variable
Total Nonobese Obese
N=1000 N=725 N=275
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Weight loss† 1.34 (1.18–1.61) 0.002 1.29 (1.04–1.60) 0.02 1.67 (1.19–2.33) 0.003
Age 1.03 (1.02–1.05) <0.001 1.04 (1.02–1.05) <0.001 1.04 (1.01–1.08) 0.02
Female sex 0.74 (0.51–1.08) 0.12 0.74 (0.47–1.18) 0.21 0.46 (0.22–96) 0.04
Ischemic etiology 1.60 (1.14–2.26) 0.007 1.43 (0.94–2.17) 0.09 2.62 (1.35–5.10) 0.004
HF duration 1.00 (1.00–1.01) 0.001 1.00 (1.00–1.01) <0.001 1.00 (1.00–1.01) 0.64
LVEF 1.00 (0.98–1.01) 0.43 0.99 (0.98–1.01) 0.26 1.00 (0.98–1.03) 0.92
NYHA functional class 1.69 (1.29–2.20) <0.001 1.89 (1.39–2.56) <0.001 1.12 (0.62–2.03) 0.70
Diabetes 1.33 (0.97–1.81) 0.07 1.14 (0.94–2.17) 0.51 2.00 (1.35–5.10) 0.02
BMI 0.99 (0.96–1.61) 0.60 0.92 (0.86–0.98) 0.007 1.04 (0.96–1.13) 0.32
b-Blockers 0.45 (0.30–0.68) <0.001 0.51 (0.31–0.85) 0.009 0.37 (0.16–0.83) 0.02
ACEI or ARB 0.44 (0.30–0.65) <0.001 0.41 (0.26–0.64) <0.001 0.51 (0.21–1.24) 0.26
MRA 0.75 (0.55–1.03) 0.07 0.79 (0.55–1.14) 0.20 0.71 (0.39–1.29) 0.26
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection
fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
†Per 1 SD decrease in weight.
Table 5. Multivariable Cox Regression Analysis for Cardiovascular Death, Using Weight Loss as Continuous Variable
Total Nonobese Obese
N=987* N=716 N=271
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Weight loss† 1.30 (1.04–1.61) 0.02 1.28 (0.98–1.06) 0.07 1.41 (0.96–2.07) 0.08
Age 1.04 (1.02–1.06) <0.001 1.04 (1.02–1.07) 0.001 1.05 (1.01–1.09) 0.02
Female sex 0.62 (0.39–0.98) 0.04 0.62 (0.35–1.11) 0.11 0.44 (0.18–1.06) 0.07
Ischemic etiology 2.07 (1.35–3.19) 0.001 1.81 (1.06–3.08) 0.03 3.36 (1.51–7.48) 0.003
HF duration 1.00 (1.00–1.01) <0.001 1.00 (1.00–1.01) <0.001 1.00 (1.00–1.01) 0.49
LVEF 1.00 (0.98–1.01) 0.54 1.00 (0.98–1.01) 0.71 0.99 (0.96–1.02) 0.49
NYHA functional class 1.70 (1.23–2.35) 0.001 1.90 (1.31–2.76) 0.001 1.07 (0.55–2.11) 0.84
Diabetes 1.62 (1.12–2.35) 0.01 1.48 (0.94–2.33) 0.09 2.17 (1.10–4.27) 0.03
BMI 1.02 (0.98–1.06) 0.34 0.96 (0.89–1.04) 0.33 1.08 (0.99–1.19) 0.08
b-Blockers 0.38 (0.23–0.62) <0.001 0.42 (0.23–0.75) 0.004 0.34 (0.13–0.86) 0.02
ACEI or ARB 0.44 (0.28–0.71) 0.001 0.39 (0.23–0.67) 0.001 0.84 (0.25–2.84) 0.78
MRA 0.89 (0.61–1.29) 0.54 0.94 (0.60–1.46) 0.78 0.85 (0.42–1.72) 0.64
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; MRA,
mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
*Thirteen patients excluded because of unknown cause of death.
†Per 1 SD decrease in weight.
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GISSI-HF—and with digoxin, treatments all associated with
the severity of HF.
Whether biomarkers are useful to mirror or as surrogate
markers of WL is unknown. Song et al33 showed an indepen-
dent association between high-sensitivity C-reactive protein
and unintentional WL in 243 patients with HF enrolled during
an index hospitalization for HF exacerbation (OR, 1.49; 95%
CI, 1.15–1.92). In the Val-HeFT “biomarker” substudy, both N-
terminal pro-brain natriuretic peptide and high-sensitivity C-
reactive protein were associated with signiﬁcant WL.31 In our
study, we found no association between signiﬁcant WL and
any of these 2 biomarkers or with ST2 and soluble transferrin
receptor. Only high-sensitivity troponin T tended to be higher
in patients with signiﬁcant WL (P=0.05), which may eventually
indicate myocyte damage caused by WL itself.
From a prognostic point of view, signiﬁcant WL was
independently associated with mortality, with an increased
risk of death of 20% (GISSI-HF) to 150% (Val-HeFT).31 In our
study, the risk of death for signiﬁcant WL after adjustment in
the multivariable model was 89% higher. Very remarkably,
among obese patients (BMI ≥30 kg/m2), signiﬁcant WL was
associated with an even higher risk of death (138% increase)
than in nonobese patients (83% increase). This ﬁnding was
very unexpected, even more so considering that low-weight
patients were not excluded from the analysis. In an analysis of
the CHARM study,34 those patients with 5% or greater WL in
6 months had a >50% increase in hazard both for cardiovas-
cular and for other causes of death compared to those with
stable weight. The impact of WL on mortality was not
signiﬁcantly related to BMI, although WL carried a particularly
high risk in patients who were already lean at study entry. In
our study, in contrast, cardiovascular mortality was almost
doubled and the patients with highest adjusted hazard of
death were the obese patients. Remarkably, in our study the
higher mortality rate observed in patients with signiﬁcant WL
was mainly caused by worsening HF. On the other hand,
although noncardiovascular death was non-negligible in our
series (23%), it was nonsigniﬁcantly higher in patients with
signiﬁcant WL.
Nevertheless, WL was not associated with an adverse
prognosis in all HF settings. The RICA Registry35 analyzed
weight changes in 731 patients admitted with acute HF during
a 1-year follow-up. One hundred ﬁfty-two patients (20.8%)
experienced WL. No differences were observed in terms of
mortality and rehospitalization between the 2 groups. These
results, observed in the acute setting in decompensated
patients, are in disagreement with our data and those of
others obtained in ambulatory, stable patients without overt
congestion.
Finally, it has been suggested that incorporating physical
activity and exercise training into a purposeful WL program
might be of beneﬁt in patients with HF.36 In the HF-ACTION
study, nonsigniﬁcant reductions in all-cause mortality and
hospitalization were observed across BMI categories,
although no association with WL was identiﬁed.9 Further
studies are needed to ascertain whether this strategy might
improve outcomes in obese patients with HF.
Limitations
The present data are based on BMI-based WL without further
anthropometric characterization (muscle or fat mass wasting
assessments), and we cannot fully ascertain whether WL
was in part intentional or nonintentional. However, the result
of intentional WL is difﬁcult to address, and most of the
analyses performed in HF trials included both intentional and
nonintentional WL as we did. We deﬁned signiﬁcant WL as a
loss of ≥5% of the initial weight during the ﬁrst year of
follow-up, as previously described.31,34,35 This cut-off can be
considered arbitrary as were all the deﬁnitions used in
previous studies; however, no deﬁnite cut-off exists. Ideally,
dry weight should be used to track WL. We only found
statistically signiﬁcant differences between patients with and
without signiﬁcant WL in NYHA functional class, sex, and
baseline BMI; nevertheless, we cannot completely discard
the possibility that they were sicker from the start, since
signiﬁcant WL is just a marker of such a situation without
playing a causative role. Further studies are needed to fully
clarify the putative causative role of signiﬁcant WL in
outcomes. We have no data on what happened to weight
during follow-up between year 1 and year 3 or the time of
death, and we only analyzed weight loss during the ﬁrst year
of follow-up. In the present study, we focused on stable
outpatients, but whether subclinical congestion may have
inﬂuenced our results remains a caveat. Although our
population is a general population attending a HF unit, the
unit is located at a tertiary university hospital and the cohort
patients are mainly male and of ischemic etiology, with the
great majority having had a hospital admission in the
previous year or a depressed LVEF. Therefore, we cannot
disregard the possibility of bias due to selection of patients
who may not necessarily represent the general HF
population.
Conclusions
Weight loss of ≥5% during 1 year in ambulatory HF patients
was associated with an ominous prognosis in the subsequent
2 years. This association was even more apparent in obese
patients. Signiﬁcant WL might not be beneﬁcial in obese HF
patients, and indiscriminate advice to lose weight in this
population might not be indicated. Further studies are needed
to ascertain whether WL and the mode of WL achievement
might ultimately be beneﬁcial in obese or even very obese
patients with HF.
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